Abstract 1560P
Background
Osemitamab (TST001) is a best-in-class humanized antibody with improved CLDN18.2 binding affinity and ADCC activity. Here, we evaluated the dynamics of on-treatment PD-L1 expression on the tumor cells in both in vivo tumor models and in vitro tumor cells and studied preclinical efficacy of the combination of Osemitamab and anti-PD-L1/PD-1 mAb +/- oxaliplatin/5-FU (Oxa/5-FU) in both CLDN18.2+/PD-L1+ and CLDN18.2+/PD-L1- tumor models.
Methods
For in vitro cell assay, we co-cultured the CLDN18.2-expressing GC cells w/wo human PBMC and 30 μg/ml Osemitamab for 72hr, and then transferred the supernatant to the matched tumor cells for another 72hr incubation. PD-L1 expression on the tumor cells was detected by using FACS analysis. The mouse with CLDN18.2-expressing tumors were injected intraperitoneally with Osemitamab or in combination with anti-PD-L1/PD-1 mAbs twice a week and injected intravenously with oxa/5-FU weekly in in vivo efficacy studies. CLDN18.2 and PD-L1 expression on the tumors was detected by using IHC analysis.
Results
We found that in the presence of human immune cells, PD-L1 expression on the CLDN18.2-expressing GC cells in vitro and tumors in vivo was upregulated after Osemitamab treatment. In two CLDN18.2+/PD-L1+ mouse syngeneic models, Osemitamab combined with Atezolizumab exhibited significantly higher tumor growth inhibition (TGI) than the single agents. Furthermore, in the same tumor model, the triplet [Osemitamab in combination with anti-mouse PD-1 (RMP1-14) + Oxa/5-FU] showed even better TGI than the doublet [Osemitamab + Oxa/5-FU or RMP1-14 + Oxa/5-FU]. Additionally, in a CLDN18.2+/PD-L1- GC PDX model with human PBMC reconstruction on B-NSG-hIL-15 mice, the Osemitamab in combination with Oxa/5-FU was also superior to either Oxa/5-FU or Oxa/5-FU + nivolumab.
Conclusions
PD-L1 upregulation after Osemitamab treatment provides a rationale for combination of Osemitamab and anti-PD-L1/PD-1 mAb. And the potential synergistic effect of Osemitamab and GC standard of care (SoC: anti-PD-1 mAb + Oxa/5-FU) in preclinical tumor models supports Osemitamab in combination with SoC chemotherapy +/- nivolumab in G/GEJ patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Suzhou Transcenta Therapeutics Co., Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1542P - Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
Presenter: Mingfang Xu
Session: Poster session 21
1543P - Clinical study of camrelizumab combined with docetaxel and carboplatin in neoadjuvant treatment of locally advanced oesophageal squamous cell carcinoma
Presenter: Rui Wang
Session: Poster session 21
1544P - Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
Presenter: Xin fang Hou
Session: Poster session 21
1545P - Phase II trial of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus
Presenter: Yuexiao Qi
Session: Poster session 21
1546P - Safety, efficacy, and biomarkers for ONO-4578 plus nivolumab in unresectable advanced or recurrent gastric or gastroesophageal cancer
Presenter: Hidekazu Hirano
Session: Poster session 21
1547P - SNP discovery based on transcriptome sequencing of whole blood RNA to find predictive biomarkers for nivolumab in gastric cancer
Presenter: Chiaki Inagaki
Session: Poster session 21
1549P - A prospective study of circulating tumor DNA (ctDNA) genomic profiling in gastric or gastroesophageal junction (GEJ) cancer patients with recurrence after adjuvant chemotherapy: Liquid-GEAR trial
Presenter: Hiroyuki Takeda
Session: Poster session 21
1551P - Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer
Presenter: Choong-kun Lee
Session: Poster session 21
1552P - Clinical multi-omics analysis of gastric cancer (GC) in Europe (EU) and Latin America (LatAm): The LEGACy project
Presenter: Tania Fleitas
Session: Poster session 21